Sparrow Pharmaceuticals

[Sparrow Pharmaceuticals @sparrowpharma]

What will 2024 bring for biopharma? Sparrow Pharmaceuticals CEO Robert Jacks shares his predictions in #pharmavoice about what to expect with the IRA, the IPO market, and investment in AI.

https://t.co/1RQ8wTKRpA

[Sparrow Pharmaceuticals @sparrowpharma]

It was a great Sunday at #ACR23 for Sparrow! Come visit us at booth #716 to learn how we are working to end the glucocorticoid-sparing era and to hear about our ongoing phase 2 clinical trial in #pmr.

[Sparrow Pharmaceuticals @sparrowpharma]

We are excited to join the world's leading rheumatologists in San Diego for #ACR2023.

Interested in partnering with Sparrow as an investigator in an upcoming clinical trial in #pmr? Visit booth #716 to learn more.

[Sparrow Pharmaceuticals @sparrowpharma]

We are very excited to announce the initiation of enrollment in a Phase 2 clinical trial of SPI-62 for ACS, a prevalent yet under appreciated condition of hypercortisolism! #ACS #Cushings #endocrinology

https://t.co/jHn2EnWkiV

[Sparrow Pharmaceuticals @sparrowpharma]

Little progress will be made in combatting #rarediseases without comprehensive public-private collaboration. Our CMO @CzerwiecFrank joined like-minded industry leaders in discussing this topic and more at the Rare and Orphan Disease Conference held by @CPathInstitute this week.

[Sparrow Pharmaceuticals @sparrowpharma]

Congratulations Sparrow team on initiation of the third cohort of PROST!, our phase 2 trial in polymyalgia rheumatica (PMR) of the HSD-1 inhibitor SPI-62 in combination with prednisolone! #pmr #rheumatology

https://t.co/BgDGQtpNaA

[Sparrow Pharmaceuticals @sparrowpharma]

We’re proud to share that our Founder & CSO @David A. Katz/davidkatz47 is joining the esteemed list of Outstanding Innovation Award recipients from @Endocrine Society/TheEndoSociety

https://t.co/hu0pND4W2u

[Sparrow Pharmaceuticals @sparrowpharma]

We’ve expanded our clinical study of ACTH-dependent Cushing’s syndrome by rolling over the first patient into the open-label extension of RESCUE, our Phase 2 clinical trial with HSD-1 inhibitor SPI-62. #endocrinology #clinicaltrials #cushings
https://t.co/26Jd7ZbcbF

[Sparrow Pharmaceuticals @sparrowpharma]

@Matt Harbert hosted CEO Robert Jacks on The Executive this week. Check out their expansive conversation here: #biopharma

https://t.co/vJoJG8JEPh

[Sparrow Pharmaceuticals @sparrowpharma]

We're in Chicago for #ENDO23! Come visit us at booth 1949 to learn about SPI-62, our novel product currently in clinical trials for #Cushings and #ACS.

[Sparrow Pharmaceuticals @sparrowpharma]

Our CEO, Robert Jacks, and CSO, David Katz, spoke with ICR’s Tom Ryan to discuss the art of drug development, the 75-year puzzle of glucocorticoids, and more. #cushings #polymyalgia #adrenal #clinicaltrials

[ICR @ICRPR]

Sparrow Pharmaceuticals' David Katz and Robert Jacks used their knowledge and innovative thinking to create a life-changing solution to an ongoing 75-year puzzle. Check out their conversation with Tom Ryan in the new episode of Welcome to the Arena: https://t.co/oVS5HTmkym

[Sparrow Pharmaceuticals @sparrowpharma]

Attending #ENDO2023? Join Sparrow CMO Frank Czerwiec and CSO David Katz as they present on SPI-62, our novel therapy in development for #Cushings syndrome. https://t.co/l6LXoxRW0D

[Sparrow Pharmaceuticals @sparrowpharma]

Does HSD-1 inhibition offer the potential to treat Cushing's syndrome and ACS with less risk of AI? Sparrow's own CMO Dr. Frank Czerwiec presented a thought provoking poster at the 25th European Congress of Endocrinology. #ECE2023

https://t.co/H0JrLhl3EU

[Sparrow Pharmaceuticals @sparrowpharma]

Sparrow CMO @CzerwiecFrank will be joining the world’s leading endocrinologists in presenting an ePoster at #ECE2023. Join him on May 13 as he discusses our research in #cushings https://t.co/JT5x10vpcH

[Sparrow Pharmaceuticals @sparrowpharma]

Sparrow is proud to support Cushing’s Awareness Day! Thank you to patient advocates like Lisa Martin. #csrf #cushings

"I have walked the same journey you are on. Know that you are worth more than what you see in the mirror. We see you and and support you."

- Lisa Martin

[Sparrow Pharmaceuticals @sparrowpharma]

Thanks #endpoints for highlighting the unmet medical needs in #pmr . Sparrow is seeking to revolutionize the treatment of autoimmune disease by sparing patients from the ravages of steroids.

https://t.co/0facCsHUTr

[Sparrow Pharmaceuticals @sparrowpharma]

Our CSO, David Katz, educating patients on the drug development process today, the last day of the CSRF/AIU conference. #csrf #cushings

[Sparrow Pharmaceuticals @sparrowpharma]

Day 2 at the joint CSRF/AIU conference! Getting to know the patients and their arduous journeys. #CSRF #cushings

[Sparrow Pharmaceuticals @sparrowpharma]

Sparrow is proud to be a sponsor at the joint CSRF/AIU conference. Come see us for more information on our Phase II clinical studies in Cushing’s and ACS! #cushings #csrf

[Sparrow Pharmaceuticals @sparrowpharma]

Congrats Sparrow team for initiating enrollment in the second cohort of our phase 2 trial of SPI-62 with prednisolone for #pmr ! #rheumatology

https://t.co/kUTYoRbhKY